GlassScriptPhysician profile
Kevin S White
NPI 1598364903
$4,246.04
in general payments reported to CMS, 2019-2025
29 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.76 · 2023: $1,131 · 2024: $1,645 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,230.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $792.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $655.81 | 2023-2025 | Airsupra, Farxiga, Tezspire |
| Pfizer INC. | $399.63 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.80 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $291.90 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $227.67 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $215.65 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $204.85 | 2023-2024 | Evenity, Prolia, Otezla |
| Medtronic, INC. | $173.94 | 2021-2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $130.11 | 2023-2025 | |
| Exact Sciences Corporation | $127.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $119.49 | 2023-2025 | Trintellix |
| Alkermes, INC. | $81.04 | 2023 | Lybalvi |
| Lundbeck LLC | $62.50 | 2024 | Vyepti |
| Alnylam Pharmaceuticals INC. | $59.18 | 2024 | Givlaari |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.83 | 2024-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $52.74 | 2023-2024 | Xarelto |
| Dexcom, INC. | $43.30 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $40.36 | 2024-2025 | Voquezna |
| Corium, LLC | $31.93 | 2023 | Adlarity |
| Esperion Therapeutics, INC. | $30.26 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $28.52 | 2023 | |
| Boston Scientific Corporation | $23.53 | 2025 | General - Erectile Dysfunction |
| Axsome Therapeutics, INC. | $21.96 | 2024 | Auvelity |
| Nevro Corp. | $20.80 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $16.29 | 2023 | Belsomra |
| Xeris Pharmaceuticals, INC. | $15.63 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2025 | Camzyos |
| Halozyme INC | $14.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.